Clinical Trial

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Protocol Amendment History 80 amendments
This ClinicalTrials.gov record has been amended 80 times since 2019-10-16; most recent amendment 2026-07-16.
Status change: Enrolling by Invitation → Active, Not Recruiting 2024-03-22
Status change: Not Yet Recruiting → Enrolling by Invitation 2019-12-03
Trial Details
NCT Number NCT04130997
Lead Sponsor TG Therapeutics, Inc.
Conditions Relapsing Multiple Sclerosis (RMS)
Enrollment 1,100 participants
Start Date 2019-11-18
Primary Completion 2032-05-31 (estimated)
Study Completion 2032-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17